Year in Review #acr22 Oral Surveillance: With ASCVD number needed to harm 16, only 223 without ASCVD Focus on risk stratification ⁦@RheumNow⁩ https://t.co/tJyha1WKfR

ORAL surveillance the big talking factor over the last year. NNH of 16(!) for CV event (over 5 yrs) in those with history of atherosclerotic CV disease. @RheumNow #ACR22 #yearinreview #ACRBest

Great start to year in review. Beginning with JAKinibs in the much talked about ORAL Surveillance study. Good Review of the mechanisms of action for JAKinibs @RheumNow #ACR22 https://t.co/IF0t4uSefj

Good grief, no! Why not get a SPECT-CT and arthroscopy on them all as well? Less is more. I will grudgingly get a plain radiograph #ACR22 https://t.co/MVx5FFRsVS

• https://twitter.com/reumatoscience/status/1591406002607382528

Abstr #0083 COVID-19 vaccine use & hesitancy among rheum pts - 34% expressed concern for safety of primary vaccine - 39% did not get booster due to not being told by physician - We need to ensure pts up to date w/ vaccine including booster https://t.co/y1vV7wbbpQ @RheumNow #ACR22 https://t.co/gcR2yOftjq

• COVID-19 Vaccine Uptake and Reasons for Hesitancy in a Large Rheumatology Pract…

#ACR22 Abstr#0355 It can take long time for Class V #lupus nephritis (membranous) to improve. Post-hoc analysis showed in 81 pts (31 pure class V), voclosporin reduced UPCR and faster vs MMF. Stable eGFR @RheumNow #ACRBest https://t.co/gXHxEAU5tq https://t.co/o280DnTmVj

• Long-term Use of Voclosporin in Patients with Class V Lupus Nephritis: Results …

#ACR22 Abstr#0349 We now have therapies for #lupus. How early should we use them? Real-world data showed 5-year risk of severe infection was reduced in Belimumab vs MTX/AZA/MMF initiators (adjusted to relevant confounders) @RheumNow https://t.co/xXg039zg7m https://t.co/9LEIyoakOY

• Comparative Risks of Infection with Belimumab versus Oral Immunosuppressants in…

Abstr #0078 Ogdie et al found that - Pts seen by rheumatologists more likely receive bDMARDs or csDMARDs - Opiates & non-Opiate pain medications were more commonly prescribed to pts seen by PCPs alone @RheumNow #ACR22 https://t.co/uDcOc0Nn3Y https://t.co/FeAq21fiVs

• Treatment of Ankylosing Spondylitis by Primary Care Physicians and Rheumatologi…

Year in Review #ACR22 GLORIA Low steroid usage: lower DAS28, reduced joint damage BUT 24% increased adverse effects ⁦@RheumNow⁩ https://t.co/vYTAhoQEqr

We want to see how you are taking in #ACR22! Share your favorite pictures from ACR on Twitter and tag #RheumPix and #ACR22 and we'll re-tweet our favorite ones! https://t.co/P41KybUuNw

Inspiring words from Dr. @cuttingforstone, "For these times, we must heed the call to adventure, find the tools & weapons never thought of before, have courage, have faith, tell our story, find our epiphanies bec this too shall pass..." #ACR22 @RheumNow #RheumTwitter https://t.co/l3DPnIBxq6

“The Stone Age did not end because we ran out of stones, it's because we found better technology.” – Dr. A. Verghese on how we need to be smarter about the practice medicine to accomplish more without being bogged down by logistics. #scribes @cuttingforstone @rheumnow #ACR22 https://t.co/20fP8cRRrv

#ACR22 Abstr#0063 How can we improve adherence of #lupus patients to therapy? Dr Sun et al. showed reviewing prescription record in clinic and ~4min honest discussion on non-adherence improved uptake in 44% at next visit @RheumNow https://t.co/jGuK4Th1lg https://t.co/62u07jDNav

• Implementability of a SLE Medication Adherence Intervention - ACR Meeting Abstr…

#ACR22 Abstr#0343 Data from SLICC cohort showed non-adherence to hydroxychloroquine (detected by HCQ level) was associated with increased risk of flares, early damage and 5-yr deaths. It’s time to monitor level in patients who are not doing so well @RheumNow https://t.co/CdFIRcSYQD